1139453-98-7

Basic information

• Product Name: N-methyl-2-(4-methylpiperazin-1-yl)-N-(4-nitrophenyl)acetamide
• Synonyms: N-methyl-2-(4-methylpiperazin-1-yl)-N-(4-nitrophenyl)acetamide;N,4-Dimethyl-N-(4-nitrophenyl)-1-piperazineacetamide;Nintedanib Intermediate 1;Intedanib Impurity 12
• CAS NO: 1139453-98-7
• Molecular Formula: C₁₄H₂₀N₄O₃
• Molecular Weight: 292
• Product Categories: Intermediate of BIBF-1120 and PKI587
• Mol File: 1139453-98-7.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 446.9±40.0 °C(Predicted)
• Appearance: /
• Density: 1.230
• Storage Temp.: 2-8°C
• Solubility: DMSO (Slightly), Methanol (Slightly)
• PKA: 7.43±0.10(Predicted)
• CAS DataBase Reference: N-methyl-2-(4-methylpiperazin-1-yl)-N-(4-nitrophenyl)acetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-methyl-2-(4-methylpiperazin-1-yl)-N-(4-nitrophenyl)acetamide(1139453-98-7)
• EPA Substance Registry System: N-methyl-2-(4-methylpiperazin-1-yl)-N-(4-nitrophenyl)acetamide(1139453-98-7)

Safety Data

• Hazardous Substances Data: 1139453-98-7(Hazardous Substances Data)

Usage

Description

N-methyl-2-(4-methylpiperazin-1-yl)-N-(4-nitrophenyl)acetamide is an organic compound that serves as a key intermediate in the synthesis of various pharmaceutical compounds. It is characterized by its molecular structure, which includes a methyl group, a piperazine ring, and a nitrophenyl group, all of which contribute to its reactivity and potential applications in the pharmaceutical industry.

Uses

Used in Pharmaceutical Industry:
N-methyl-2-(4-methylpiperazin-1-yl)-N-(4-nitrophenyl)acetamide is used as a reactant in the synthetic preparation of 6-methoxycarbonyl-substituted indolinones. One such example is Intedanib (I666650), which is a triple angiokinase inhibitor and antitumor agent. N-methyl-2-(4-methylpiperazin-1-yl)-N-(4-nitrophenyl)acetamide plays a crucial role in the development of cancer treatments by providing a starting point for the synthesis of potent antitumor drugs.

Upstream product

• 109-01-3 1-methyl-piperazine 
• 2653-16-9 2-chloro-N-methyl-N-(4-nitrophenyl)acetamide 
• 23543-31-9 2-bromo-N-methyl-N-(4-nitrophenyl)acetamide 
• 100-15-2 N-methyl(p-nitroaniline) 
• 586-78-7 para-nitrophenyl bromide 

Downstream Products

• 262368-30-9 N-[(4-methyl-piperazin-1-yl)methylcarbonyl]-N-methyl-p-phenylendiamine 
• 656247-17-5 nintedanib 
• 262366-32-5 (Z)-N-methyl-2-(4-methylpiperazin-1-yl)-N-(4-(((2-oxoindolin-3-ylidene)(phenyl)methyl)amino)phenyl)acetamide 
• 894783-71-2 BIBF 1202 

Relevant articles and documents

Design, synthesis and biological evaluation of deuterated nintedanib for improving pharmacokinetic properties

Nintedanib is a novel triple angiokinase inhibitor that inhibits three growth factors simultaneously. Deuterated derivatives of nintedanib at certain metabolically active sites were prepared and evaluated in vitro and in vivo. In particular, deuterated compound SKLB-C2202 had significantly improved pharmacokinetic properties compared with nintedanib. These efforts lay the foundation for further investigating the druggability of SKLB-C2202. Deuterated derivatives of nintedanib at certain metabolically active sites were prepared and evaluated in vitro and in vivo. Deuterated compound SKLB-C2202 had significantly improved pharmacokinetic properties compared with nintedanib. Further research is underway.

Preparation method of amino intermediate (by machine translation)

Compared with an existing preparation method, the method for preparing. the amine-based (I) intermediate disclosed by the invention comprises the following, steps: carrying (III) out condensation, reduction and the like of the compound of. the formula I to obtain, the target compound (I), and 1 remarkably reducing the, content of the impurities in the obtained compound according to the, invention as compared with the existing preparation. method. (by machine translation)

INDOLINONE DERIVATIVES AS INHIBITORS OF MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE

The present disclosure relates to indolinone compounds, compositions, and methods for the inhibition of maternal embryonic leucine zipper kinase (MELK). The present disclosure further relates to indolinone compounds, compositions, and methods for the treatment or prevention of a cancer (for example, triple negative breast cancer).